Attributable Healthcare Resource Utilization and Costs for Patients With Primary and Recurrent Clostridium difficile Infection in the United States

Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach

(2016) Kamal Desai et al.   BMC INFECTIOUS DISEASES

Bloom and bust: intestinal microbiota dynamics in response to hospital exposures and Clostridium difficile colonization or infection

(2016) Caroline Vincent et al.   Microbiome

Economic burden of Clostridium difficile associated diarrhoea: a cost-of-illness study from a German tertiary care hospital

(2015) S. M. Heimann et al.   INFECTION

Burden of Clostridium difficile Infection in the United States

(2015) Fernanda C. Lessa et al.   NEW ENGLAND JOURNAL OF MEDICINE

Guidelines for good pharmacoepidemiology practice (GPP)

(2015)   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Attributable Inpatient Costs of Recurrent Clostridium difficile Infections

(2014) Erik R. Dubberke et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Strategies to Prevent Clostridium difficile Infections in Acute Care Hospitals: 2014 Update

(2014) Erik R. Dubberke et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Epidemiology of Clostridium difficile Infection and Risk Factors for Unfavorable Clinical Outcomes: Results of a Hospital-Based Study in Barcelona, Spain

(2013) D. Rodriguez-Pardo et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Length of stay and hospital costs among high-risk patients with hospital-originClostridium difficile-associated diarrhea

(2013) Rebecca Campbell et al.   JOURNAL OF MEDICAL ECONOMICS

An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies

(2011) Peter C. Austin   MULTIVARIATE BEHAVIORAL RESEARCH

Fidaxomicin versus Vancomycin forClostridium difficileInfection

(2011) Thomas J. Louie et al.   NEW ENGLAND JOURNAL OF MEDICINE

Incidence, case fatality and genotypes causing Clostridium difficile infections, Finland, 2008* *Parts of the results were previously presented at the 19th Annual Scientific Meeting of The Society for Healthcare Epidemiology of America (SHEA) 03/2009, San Diego, CA, USA and the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 05/2009, Helsinki, Finland.

(2010) S.M. Kotila et al.   CLINICAL MICROBIOLOGY AND INFECTION

Multicenter Study of Clostridium difficile Infection Rates from 2000 to 2006

(2010) Erik R. Dubberke et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Treatment with Monoclonal Antibodies againstClostridium difficileToxins

(2010) Israel Lowy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Health Care–AssociatedClostridium difficileInfection in Adults Admitted to Acute Care Hospitals in Canada: A Canadian Nosocomial Infection Surveillance Program Study

(2009) Denise Gravel et al.   CLINICAL INFECTIOUS DISEASES

Recurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes

(2009) Stuart Johnson   JOURNAL OF INFECTION

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: The ISPOR Drug Cost Task Force Report—Part IV

(2009) C. Daniel Mullins et al.   VALUE IN HEALTH

Meta-analysis to assess risk factors for recurrent Clostridium difficile infection

(2008) K.W. Garey et al.   JOURNAL OF HOSPITAL INFECTION

Clostridium difficile— More Difficult Than Ever

(2008) Ciarán P. Kelly et al.   NEW ENGLAND JOURNAL OF MEDICINE